Prescription drug aripiprazole tablets recalled for manufacturing practice deviations
Accord Healthcare is recalling aripiprazole tablets (30 mg) due to manufacturing practice deviations found during an FDA inspection. The recall covers 88,728 bottles distributed to the United States, Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall initiated due to manufacturing practice deviations identified during FDA inspection, with no reported illnesses or injuries. The recall is precautionary in nature, based on compliance violations rather than direct patient harm.
Plain-English summary
Accord Healthcare, Inc. is recalling Aripiprazole Tablets, USP 30 mg distributed under the brand ARIPIPRAZOLE. The recall includes 88,728 bottles in both 30-count and 100-count package sizes distributed to the United States, including Puerto Rico and Canada.
The recall was initiated following an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations. This is a Class II recall.
Consumers who have obtained affected bottles should consult their healthcare provider or pharmacist regarding the recall. Specific batch codes and expiration dates are provided in the official FDA recall notice to help identify affected medication.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Accord Healthcare, Inc.
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (17)
- Batches: a) P2005477
- Exp. Date 9/30/2023
- P2100002
- Exp. Date 12/31/2023
- P2101359 Exp. Date 2/28/2024
- P2105409
- Exp. Date 7/31/2024
- P2107447
- Exp. Date 10/31/2024
- P2203388 Exp. Date 5/31/2025
- b) P2101859 Exp. Date 2/28/2023
- P2107056
- Exp. Date 10/31/2023
- P2203066
- Exp. Date 5/31/2024
- P2206130
- Exp. Date 8/31/2024
UPCs (2)
- 316729283106
- 316729283014
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole tablets recalled nationwide due to excess active ingredient
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- ModerateAripiprazole Tablets Recalled Following FDA Inspection for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole 15 mg Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27